Decipher is now part of Veracyte!     Learn More
Decipher is now part of Veracyte!     Learn More
Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary *UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
Toggle Summary Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot Campaign in North Carolina


Date Event Details
Summary Toggle Apr 13, 2021 2:15 PM EDT
20th Annual Needham Virtual Healthcare Conference


Title Documents

Corporate Presentation April 2021